The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.

@article{Mori2014TheSA,
  title={The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.},
  author={Masamichi Mori and Yoko Ueno and Satoshi Konagai and Hiroshi Fushiki and Itsuro Shimada and Yutaka Kondoh and Rika Saito and Kenichi Mori and Nobuaki Shindou and Takatoshi Soga and Hideki Sakagami and Takashi Furutani and Hitoshi Doihara and Masafumi Kudoh and Sadao Kuromitsu},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 2},
  pages={329-40}
}
Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC). Echinoderm microtubule-associated protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC. Here, we investigated the effects of ASP3026, a novel small-molecule ALK inhibitor, against ALK-driven NSCLC. ASP3026 inhibited… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…